

S12 Table. Characteristics of participants in derivation and validation samples.

	Derivation sample N=2726	Validation sample N=478
WHO region of enrolment		
Africa	849 (31.1%)	149 (31.2%)
Americas	68 (2.5%)	11 (2.3%)
South-East Asia	1021 (37.5%)	180 (37.7%)
Europe	103 (3.8%)	18 (3.8%)
Western Pacific	685 (25.1%)	120 (25.1%)
Age at baseline (days), median (IQR)	5 (1, 15)	4 (1, 14)
Birth weight (grams), median (IQR)	2497.5 (1400, 3187.5)	2500 (1400, 3200)
Gestational age at birth (weeks), median (IQR)	37 (31, 39)	37 (31, 39)
Time from admission to enrolment (hours), median (IQR)	21 (1, 128)	27 (1, 117)
Congenital anomalies	228 (8.4%)	37 (7.7%)
Sepsis group		
Early onset (age <48 hrs)	898 (32.9%)	168 (35.1%)
Late onset community associated, term	619 (22.7%)	89 (18.6%)
Late onset healthcare associated, pre-term	799 (29.3%)	137 (28.7%)
Other	410 (15.0%)	84 (17.6%)
Maximum ventilation support at baseline		
None	993 (36.4%)	172 (36.0%)
Oxygen supplementation	517 (19.0%)	102 (21.3%)
CPAP, BiPAP, high flow nasal cannulae	615 (22.6%)	104 (21.8%)
Invasive ventilation	601 (22.0%)	100 (20.9%)
Temperature at baseline		
<35.5C	50 (1.8%)	8 (1.7%)
35.5-37.9C	2332 (85.7%)	404 (84.5%)
>=38-<39C	268 (9.9%)	52 (10.9%)
>=39C	70 (2.6%)	14 (2.9%)
Difficulty feeding at baseline	1226 (45.0%)	239 (50.0%)
Lethargy, no/reduced movement at baseline		
Neither	1772 (65.0%)	301 (63.0%)
Lethargy only	674 (24.7%)	129 (27.0%)
Reduced/no movement	280 (10.3%)	48 (10.0%)
Abdominal distension at baseline	665 (24.4%)	112 (23.4%)
Evidence of shock including cold peripheries at baseline	578 (21.2%)	105 (22.0%)
Cyanosis at baseline	329 (12.1%)	55 (11.5%)
Baseline blood culture positive (pathogen)	484 (17.8%)	80 (16.7%)
Died, overall ¹	308 (11.3%)	42 (8.8%)
Died on IV antibiotics ²	248 (9.1%)	38 (7.9%)